When diagnosed with a disease, it’s often overwhelming to sort through mountains of medical data to figure out what therapies are available, pinpoint where they’re offered and identify the best experts to help. Complexity specialist Gunjan Bhardwaj recognizes that mining this information may best be done using a system of artificial intelligence and blockchain to help people, within and outside the medical field, navigate and comprehend such “deep, dense and diverse” data — entering a new era where all research is searchable and shareable.

Gunjan Bhardwaj studied at IIT Bombay, FH Pforzheim, MIT Sloan and EBS Oestrich-Winkel. He founded Innoplexus in 2011, a technology and product development company focused on solving challenges in life sciences and pharmaceuticals using artificial intelligence. Previously, he worked for BCG and EY. He has authored numerous articles for the Harvard Business Review, the MIT Sloan Review and other journals, and has advised businesses and nonprofit organizations. He lectures at the Frankfurt School of Finance and other schools.

Innoplexus, a leading AI and Life Sciences company, raises double-digit million dollar series C round from FinLab EOS VC and others

Frankfurt, Germany – Innoplexus AG, a leading global artificial intelligence (AI) company with over 80 patent applications in AI, machine learning and blockchain technologies, has received series C funding in the sum of double-digit millions. The round was co-led by FinLab EOS VC Fund, a venture capital fund backed by both Block.one, the publisher of the blockchain protocol EOSIO, and FinLab AG, one of Europe’s largest company builders and investors focused on financial services technologies. The FinLab EOS VC Fund invests across sectors and focuses on projects delivering value through the application of the EOSIO blockchain technology. Innoplexus AG represents FinLab EOS VC Fund’s largest investment to date.

Co-lead investor was existing shareholder ATAI Life Sciences, a global biotech company builder focused on developing breakthrough innovations in mental health. Innoplexus and ATAI closely cooperate to make the drug development process in mental health more effective and efficient by utilizing Innoplexus’ technology.

Innoplexus will use the funding to continue developing its AI and blockchain solutions and for international commercial expansion. “We are pleased to have gained yet another strong investor with the FinLab EOS VC Fund, who will support us to scale even further with their know-how and network,” says Dr. Gunjan Bhardwaj, Founder and CEO of Innoplexus.

Innoplexus’ products & solutions are used by global pharmaceutical and biotechnology companies as well as Clinical Research Organizations generating actionable insights across the drug development life cycle. The company is ushering in a new paradigm in drug discovery and development with its domain specific AI. Innoplexus is working with cutting edge technologies related to information retrieval, network analysis, computer vision, entity normalization and ontologies and has a strong focus on creating proprietary intellectual property.

“We fully believe in the mission of Innoplexus and will support them in transforming drug discovery and development into the areas of AI and blockchain. By integrating the EOSIO protocol, meaningful unpublished data could also be used for research. Innoplexus is leveraging the EOSIO blockchain to integrate unpublished data, as well as information that is trapped in silos, to aggregate growing data oceans and to accelerate drug discovery and development,’’ shares Juan Rodriguez, Managing Director of FinLab EOS VC Fund.

Image Credit: Innoplexus

News This Week

The Precarious Asymmetries of Human-AI Relationships

KEY POINTS Human-AI interactions are currently asymmetrical, lacking continuity and depth. AI evolution may lead to more sustained, contextually rich user relationships. Balancing asymmetry and connection requires design advocacy and technological adaptations. As artificial intelligence (AI) [...]